These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 6850822)

  • 1. So-called "tension headache"--the response to a 5-HT uptake inhibitor: femoxetine.
    Sjaastad O
    Cephalalgia; 1983 Mar; 3(1):53-60. PubMed ID: 6850822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Femoxetine in the prophylaxis of migraine--a randomised comparison with placebo.
    Zeeberg I; Orholm M; Nielsen JD; Honore PL; Larsen JJ
    Acta Neurol Scand; 1981 Dec; 64(6):452-9. PubMed ID: 6753446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propranolol and femoxetine, a HT-uptake inhibitor, in migraine prophylaxis. A double-blind crossover study.
    Andersson PG; Petersen EN
    Acta Neurol Scand; 1981 Oct; 64(4):280-8. PubMed ID: 7032183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Femoxetine - a new 5-HT uptake inhibitor - and propranolol in the prophylactic treatment of migraine.
    Kangasniemi PJ; Nyrke T; Lang AH; Petersen E
    Acta Neurol Scand; 1983 Oct; 68(4):262-7. PubMed ID: 6606930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo.
    Schrader H; Kayed K; Bendixen Markset AC; Treidene HE
    Acta Neurol Scand; 1986 Oct; 74(4):297-303. PubMed ID: 3544654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of whole blood serotonin in depressed patients treated with a new, selective serotonin-uptake inhibitor, femoxetine.
    Børup C; Petersen IM; le Fèvre Honoré P; Wetterberg L
    Psychopharmacology (Berl); 1979 Jun; 63(3):241-3. PubMed ID: 113809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Femoxetine in the treatment of obese patients in general practice. A randomized group comparative study with placebo.
    Bitsch M; Skrumsager BK
    Int J Obes; 1987; 11(2):183-90. PubMed ID: 3301710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Femoxetine and amitriptyline in general practice: a randomized double-blind group comparison.
    Skrumsager BK; Jeppesen K
    Pharmacopsychiatry; 1986 Sep; 19(5):368-77. PubMed ID: 3774871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in platelet function and blood serotonin level in migraine patients during treatment with femoxetine.
    Dalsgaard-Nielsen J; le Fèvre Honoré P; Zeeberg I
    Acta Neurol Scand; 1982 Aug; 66(2):191-8. PubMed ID: 6982585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of 5-HT uptake into neurons and platelets in mice treated chronically with chlorimipramine and femoxetine.
    Buus Lassen J; Lund J; Bechgaard E; Søndergaard I
    Psychopharmacology (Berl); 1979 Aug; 64(2):149-53. PubMed ID: 115034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular (ECG and systolic time intervals) and anticholinergic effects of repeated doses of femoxetine--a comparison with amitriptyline and placebo in healthy men.
    Warrington SJ; Turner P; Skrumsager BK
    Br J Clin Pharmacol; 1989 Mar; 27(3):343-51. PubMed ID: 2719894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled double-blind study of femoxetine and amitriptyline in patients with endogenous depression.
    Reebye PN; Yiptong C; Samsoon J; Schulsinger F; Fabricius J
    Pharmacopsychiatria; 1982 Sep; 15(5):164-9. PubMed ID: 6757983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression.
    Dunner DL; Cohn JB; Walshe T; Cohn CK; Feighner JP; Fieve RR; Halikas JP; Hartford JT; Hearst ED; Settle EC
    J Clin Psychiatry; 1992 Feb; 53 Suppl():57-60. PubMed ID: 1531827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine.
    Orholm M; Honoré PF; Zeeberg I
    Acta Neurol Scand; 1986 Sep; 74(3):235-9. PubMed ID: 3538753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Treatment of obesity by femoxetine a selective 5 HT reuptake inhibitor'.
    Smedegaard J; Christiansen P; Skrumsager B
    Int J Obes; 1981; 5(4):377-8. PubMed ID: 7309322
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and tolerance of femoxetine and imipramine in the treatment of depressive states. A randomized, double-blind study.
    Suominen J; Tamminen T; Elosuo R; Manniche PM
    Pharmacopsychiatry; 1988 Sep; 21(5):238-44. PubMed ID: 3067246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antidepressant effects of 5-HT uptake inhibitors.
    Aberg-Wistedt A
    Br J Psychiatry Suppl; 1989 Dec; (8):32-40. PubMed ID: 2692638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amitriptyline, a combined serotonin and noradrenaline re-uptake inhibitor, reduces exteroceptive suppression of temporal muscle activity in patients with chronic tension-type headache.
    Bendtsen L; Jensen R; Olesen J
    Electroencephalogr Clin Neurophysiol; 1996 Oct; 101(5):418-22. PubMed ID: 8913195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of obesity in general practice with femoxetine. A controlled clinical trial of the effects of femoxetine and placebo].
    Kristensen JS; Christiansen P; Skrumsager BK
    Ugeskr Laeger; 1982 Mar; 144(13):939-42. PubMed ID: 7048680
    [No Abstract]   [Full Text] [Related]  

  • 20. Salivation after single-doses of the new antidepressants femoxetine, mianserin and citalopram. A cross-over study.
    Clemmesen L; Jensen E; Min SK; Bolwig TG; Rafaelsen OJ
    Pharmacopsychiatry; 1984 Jul; 17(4):126-32. PubMed ID: 6591216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.